On November 6, 2023 MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported that the first patient has been treated as part of its Phase 2b trial, called PHOEBUS, investigating the efficacy of MaaT033 in improving overall survival (OS) at 12 months for patients with blood cancer receiving allo-HSCT (Press release, MaaT Pharma, NOV 6, 2023, View Source [SID1234637036]). The trial is an international, multi-center, randomized, double-blind, placebo-control study (NCT05762211), which will be conducted in up to 56 clinical investigation sites and is expected to enroll 387 patients. It is to date the largest randomized controlled trial assessing a microbiome therapy in oncology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Today marks a significant milestone for us as our second product, MaaT033, enters Phase 2b clinical trials in allo-HSCT. The opportunity to offer patients a capsule that can be taken at home not only furthers our overall mission to improve patient survival in multiple situations, but also reinforces our leadership in the field, as we believe this program is currently the most advanced in the microbiome/hemato-oncology field," said Hervé Affagard, CEO and co-founder of MaaT Pharma.
Prof. Florent Malard, Professor of Hematology at the Saint-Antoine Hospital and Sorbonne University, and principal investigator of the study added, "A growing body of evidence indicates that gut imbalance leads to higher mortality in our field. By directly targeting to restore the gut microbiome richness in patients receiving harsh and deleterious treatments, our goal is to ensure optimal microbiome functions that can potentially lead to improved hematopoietic and immune recovery as well as overall survival."
To date, the Company has received regulatory approvals from France and Germany, and the clinical trial will be expanded to sites in additional countries subject to regulatory approval.
Study objectives:
Primary endpoint: Overall Survival, evaluated in late 2026.
Secondary endpoints include evaluation of safety and tolerability before and after allo-HSCT, and evaluation of the engraftment of beneficial microbial species from MaaT033.
About MaaT033
MaaT033, a donor-derived, high-richness, high-diversity oral Microbiome Ecosystem TherapyTM containing anti-inflammatory ButycoreTM species, is currently being developed as an adjunctive therapy to improve overall survival in patients receiving HSCT and other cellular therapies. It aims to ensure optimal microbiota function and to address a larger patient population in a chronic setting. MaaT033 has been granted Orphan Drug Designation by the European Medicines Agency (EMA) in August 2023.
About Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) for liquid tumors can replace cancerous cells, but the harsh conditioning treatments damage the gut microbiome, which has been linked to decreased survival, increased risk of graft-vs-host disease, and infections due to impaired immune function. Nearly 20,000 allo-HSCT transplantations per year in Europe were reported in 2021 by the European Society for Blood and Marrow Transplantation (EBMT) and continue to increase.